Corgentech Overview
- Year Founded
-
1999
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$124M
Corgentech General Information
Description
Provider of biopharmaceutical products and services based in San Francisco, California. The company is engaged in discovery, development and commercialization of a new class of therapeutics called transcription factor decoys.
Contact Information
Website
www1.corgentech.comCorporate Office
- 650 Gateway Boulevard
- South San Francisco, CA 94080
- United States
Corporate Office
- 650 Gateway Boulevard
- South San Francisco, CA 94080
- United States
Corgentech Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 8. Merger/Acquisition | 26-Sep-2005 | $124M | Completed | Profitable | ||
| 7. PIPE | Completed | Profitable | ||||
| 6. IPO | 12-Feb-2004 | Completed | Profitable | |||
| 5. Later Stage VC (Series D) | 20-Oct-2003 | Completed | Profitable | |||
| 4. Later Stage VC | 17-Oct-2003 | Completed | Profitable | |||
| 3. Later Stage VC (Series D) | 10-Oct-2002 | Completed | Product Development | |||
| 2. Early Stage VC (Series B) | 01-May-2001 | $13M | $15.5M | Completed | Product Development | |
| 1. Early Stage VC (Series A) | 01-Feb-1999 | $2.5M | $2.5M | Completed | Product Development |
Corgentech Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B1 | ||||||||
| Series B | 10,000,000 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 12.65% |
| Series A | 4,325,254 | $0.001000 | 8% | $0.58 | $0.58 | 1x | $0.58 | 5.47% |
Corgentech Former Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alta Partners | Venture Capital | Minority | ||
| Axiom Venture Partners | Venture Capital | Minority | ||
| Bear Stearns Health InnoVentures Management | Venture Capital | Minority | ||
| Bristol-Myers Squibb | Corporation | Minority | ||
| CCMP Capital Advisors | PE/Buyout | Minority |
Corgentech Acquisitions (1)
Corgentech’s most recent deal was a Reverse Merger with Anesiva. The deal was made on 26-Sep-2005.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Anesiva | 26-Sep-2005 | Reverse Merger | Drug Discovery |
Corgentech FAQs
-
When was Corgentech founded?
Corgentech was founded in 1999.
-
Where is Corgentech headquartered?
Corgentech is headquartered in South San Francisco, CA.
-
What industry is Corgentech in?
Corgentech’s primary industry is Biotechnology.
-
Is Corgentech a private or public company?
Corgentech is a Private company.
-
What is the current valuation of Corgentech?
The current valuation of Corgentech is .
-
What is Corgentech’s current revenue?
The current revenue for Corgentech is .
-
How much funding has Corgentech raised over time?
Corgentech has raised $216M.
-
Who are Corgentech’s investors?
Alta Partners, Axiom Venture Partners, Bear Stearns Health InnoVentures Management, Bristol-Myers Squibb, and CCMP Capital Advisors are 5 of 16 investors who have invested in Corgentech.
-
When was Corgentech acquired?
Corgentech was acquired on 26-Sep-2005.
-
Who acquired Corgentech?
Corgentech was acquired by Anesiva.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process